Covington and Wilson Sonsini have advised Odyssey Therapeutics. Cooley has advised the underwriters. Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on autoimmune and inflammatory diseases,...
Odyssey Therapeutics Announces $304 Million Upsized IPO and Private Placement
Enlaza and Vertex Pharmaceuticals Enter Multi-Target Drug Discovery Collaboration
Cooley and Wilson Sonsini Goodrich & Rosati have advised Enlaza Therapeutics, and Covington has advised Vertex Pharmaceuticals. Enlaza Therapeutics has entered into a multi-target drug discovery...
Enlaza Therapeutics’ $100 Million Series A Financing Round
Wilson Sonsini Goodrich & Rosati advised Enlaza on IP matters related to the transaction. Enlaza Therapeutics (Enlaza), the first covalent biologic platform company, announced it closed...
Boundless Bio’s $100 Million IPO
Latham & Watkins and Wilson Sonsini Goodrich & Rosati advised Boundless Bio on the offering, and Cooley advised the underwriters. Boundless Bio, Inc. (Nasdaq: BOLD) a clinical...
Unilever’s Acquisition of K18
Wilson Sonsini Goodrich & Rosati is advising K18 on the transaction. Unilever announced it signed an agreement to acquire premium biotech haircare brand K18. Founded in 2020...
Sudo Biosciences’s $116 Million Series B Financing Round
Wilson Sonsini Goodrich & Rosati advised Sudo on intellectual property matters related to the transaction. Sudo Biosciences (“Sudo”) announced the close of a $116 million Series B...
Boundless Bio’s $100 Million Series C Financing
Wilson Sonsini Goodrich & Rosati advised Boundless Bio on IP matters related to the transaction. Boundless Bio, a clinical-stage, next-generation precision oncology company developing innovative therapeutics...
Rivus Pharmaceuticals’ $132 Million Series B Financing
Wilson Sonsini Goodrich & Rosati advised RA Capital Management on the deal. Rivus Pharmaceuticals, a clinical-stage biopharmaceutical company dedicated to improving cardio-metabolic health, announced the completion...
Belite Bio’s $36 Million IPO
Wilson Sonsini Goodrich & Rosati and O’Melveny advised Belite Bio on the deal. Belite Bio, Inc., a clinical-stage biopharmaceutical drug development company, announced the pricing of...
Ambagon Therapeutics’ $85 Million Series A Financing
Wilson Sonsini Goodrich & Rosati advised Ambagon Therapeutics on the deal. Ambagon Therapeutics, a biotechnology company unlocking intrinsically disordered proteins and other difficult-to-target protein classes, announced...
BIOMILQ, Inc.’s $21 Million Series A Financing
Wilson Sonsini Goodrich & Rosati advised Novo Holdings on the deal. North Carolina-based mammary biotechnology company BIOMILQ, Inc., announced the successful close of $21 million in...
Erasca’s $345 Million Initial Public Offering
Latham & Watkins LLP and Wilson Sonsini Goodrich & Rosati represented Erasca in the transaction. Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on...